Taking stock of the drug industry, from the lab to the medicine chestSeptember 13, 2023Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer CHANDAN KHANNA/AFP via Getty Images STAT+ | In new Regeneron deal for Covid drug, White House imposes price limits for first time A clause in a new deal between HHS and Regeneron is the first time the White House has directly challenged drugs' list prices. By Rachel Cohrs STAT+ | Lawmakers introduce bill to require drugmakers to provide key info to both FDA and U.S. Patent Office The goal is to ensure the FDA and PTO coordinate efforts to prevent drug companies from unfairly extending monopolies on their medicines. By Ed Silverman STAT+ | FDA panel endorses Alnylam's heart drug — after picking apart its supporting data The FDA panel found the benefits of Alnylam's drug, patisiran, outweighed its risks for patients with the progressive heart disease ATTR-CM. By Damian Garde Evan Vucci/AP STAT+ | What to make of Biden's latest Cancer Moonshot efforts President Biden's latest Cancer Moonshot efforts are inspiring hope among cancer researchers, but not everyone is impressed. By Sarah Owermohle and Angus Chen STAT+ | Opinion: The IRA needs changes to better support patients with rare diseases The explosion of new treatments for patients living with rare diseases could be undermined by CMS and the Inflation Reduction Act. By Rachel King and Peter L. Saltonstall Opinion: PEPFAR, one of the greatest public health inventions of our time, is at risk PEPFAR has navigated more than just the AIDS epidemic. We need it now more than ever, so Congress needs to act. By Arjun Sharma More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments